摘要
目的评价泮托拉唑对急性冠脉综合征患者氯吡格雷抗血小板作用的影响。方法200例急性冠脉综合征患者在给予阿司匹林(一日100 mg)和氯吡格雷(一日75 mg)基础上,随机分为治疗组(增服泮托拉唑一日40 mg)和对照组(不增服任何质子泵抑制剂),于服用阿司匹林和氯吡格雷前及服用7 d后检测二磷酸腺苷诱导的血小板聚集率。结果共计190例最终入选(治疗组94例,对照组96例)。与服用前相比,服用阿司匹林和氯吡格雷后两组血小板聚集率均明显降低(P=0.000)。治疗组与对照组相比,无论服药前后,血小板聚集率差异均无统计学意义(服用前P=0.997,服用后P=1.000)。两组各有6例血小板聚集率降低幅度低于20%,其中对照组1例降低幅度小于10%。结论泮托拉唑对急性冠脉综合征患者氯吡格雷的抗血小板聚集效应无显著影响。
Objective To evaluate the impact of pantoprazole on clopidogrel＇s anti-platelet effect in patients with acute coronary syndrome （ACS）. Methods Two hundred patients with ACS treated with aspirin （100 mg/d） and clopidogrel （75 mg/d） were randomly divided into the treatment group （pantoprazole 40 mg/d） and control group （no proton pump inhibitor administered） .The platelet aggregation rate was detected before and after administration of aspirin and clopidogrel. Results A total of 190 patients were ultimately enrolled （94 in the treatment group and 96 in the control group）. The platelet aggregation rate significantly decreased after the administration of aspirin and clopidogrel in both groups （P=0.000）. Comparison between the two groups showed no statistically significant difference in platelet aggregation rate before or after administration （before P=0.997, after P=1.000）. In both groups, there were six cases of platelet aggregation rate decreased by less than 20%, among which one case showed a decrease by less than 10% in the control group. Conclusion There are no significant impact of pantoprazole on clopidogrel＇s anti-platelet effect in patients with ACS.
出处
《世界临床药物》
CAS
2012年第8期471-473,481,共4页
World Clinical Drug
基金
上海市卫生局青年科研基金(2009Y130)
